- Home
- RBOT vs IFRX Comparison
RBOT vs IFRX Comparison
Compare RBOT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- IFRX
- Stock Information
- Founded
- RBOT 2014
- IFRX 2007
- Country
- RBOT United States
- IFRX Germany
- Employees
- RBOT N/A
- IFRX N/A
- Industry
- RBOT Medical Specialities
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- IFRX Health Care
- Exchange
- RBOT Nasdaq
- IFRX Nasdaq
- Market Cap
- RBOT 45.8M
- IFRX 53.5M
- IPO Year
- RBOT N/A
- IFRX 2017
- Fundamental
- Price
- RBOT $9.32
- IFRX $0.80
- Analyst Decision
- RBOT Hold
- IFRX Strong Buy
- Analyst Count
- RBOT 1
- IFRX 4
- Target Price
- RBOT $8.50
- IFRX $7.75
- AVG Volume (30 Days)
- RBOT 35.2K
- IFRX 213.0K
- Earning Date
- RBOT 08-12-2025
- IFRX 08-07-2025
- Dividend Yield
- RBOT N/A
- IFRX N/A
- EPS Growth
- RBOT N/A
- IFRX N/A
- EPS
- RBOT N/A
- IFRX N/A
- Revenue
- RBOT N/A
- IFRX $191,224.00
- Revenue This Year
- RBOT N/A
- IFRX N/A
- Revenue Next Year
- RBOT N/A
- IFRX $1,276.37
- P/E Ratio
- RBOT N/A
- IFRX N/A
- Revenue Growth
- RBOT N/A
- IFRX 54.36
- 52 Week Low
- RBOT $4.27
- IFRX $0.71
- 52 Week High
- RBOT $19.00
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- RBOT 50.57
- IFRX 39.19
- Support Level
- RBOT $8.69
- IFRX $0.74
- Resistance Level
- RBOT $9.58
- IFRX $0.92
- Average True Range (ATR)
- RBOT 0.94
- IFRX 0.07
- MACD
- RBOT -0.21
- IFRX -0.00
- Stochastic Oscillator
- RBOT 15.63
- IFRX 28.33
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.